Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

BACKGROUND: In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined rituximab and bortezomib (R-bortezomib), compared to single agent bortezomib. Therefore, we evaluated R-bortezomib in a preclinical model and in a pha...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Baiocchi, Robert A., Alinari, Lapo, Lustberg, Mark E., Lin, Thomas S., Porcu, Pierluigi, Li, Xiaobai, Johnston, Jeffrey S., Byrd, John C., Blum, Kristie A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3116936/
https://ncbi.nlm.nih.gov/pubmed/24048792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25792
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller